卫光生物：拟设合资公司，建设深圳市细胞与基因治疗市场化公共服务平台

Core Viewpoint - The company plans to establish a joint venture named Shenzhen Xihe Life Technology Co., Ltd. with three other firms to create a public service platform for cell and gene therapy in Shenzhen [1] Group 1 - The initial registered capital of Shenzhen Xihe Life Technology is set at 100 million RMB [1] - The company will contribute 40 million RMB, representing a 40% equity stake in the joint venture [1] - The other partners in the joint venture include Shenzhen Shenye Biomedical Industry Development Co., Ltd., Shenzhen Cell Valley Biomedical Co., Ltd., and Shenzhen Saiqiao Biotech Innovation Technology Co., Ltd. [1]